Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model

Claudia María García-Cuellar; Claudio Cabral-Romero; Rene Hernández-Delgadillo; Juan Manuel Solis-Soto; Irene Meester; Yesennia Sánchez-Pérez; Sergio Eduardo Nakagoshi-Cepeda; Nayely Pineda-Aguilar; Rosa Isela Sánchez-Nájera; María Argelia Akemi Nakagoshi-Cepeda; Shankararaman Chellam

doi:10.2174/1871520622666220215124434

Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model

Claudia María García-Cuellar, Claudio Cabral-Romero, Rene Hernández-Delgadillo, Juan Manuel Solis-Soto, Irene Meester, Yesennia Sánchez-Pérez, Sergio Eduardo Nakagoshi-Cepeda, Nayely Pineda-Aguilar, Rosa Isela Sánchez-Nájera, María Argelia Akemi Nakagoshi-Cepeda, Shankararaman Chellam

Departamento Académico

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Aim: The objective of this study was to analyze the antitumor effect of BisBAL NP in a mouse melanoma model. Materials and Methods: The antitumor activity of BisBAL NP on murine B16-F10 melanoma cells was determined both in vitro (PrestoBlue cell viability assay and Live/Dead fluorescence) and in vivo, in a mouse model, with the following 15-day treatments: BisBAL NP, negative control (PBS), and cell-death control (docetaxel; DTX). Mouse survival and weight, as well as the tumor volume, were recorded daily during the in vivo study. Results: BisBAL NP were homogeneous in size (mean diameter, 14.7 nm) and bismuth content. In vitro, 0.1 mg/mL BisBAL NP inhibited B16-F10 cell growth stronger (88%) than 0.1 mg/mL DTX (82%) (*p<0.0001). In vivo, tumors in mice treated with BisBAL NP (50 mg/kg/day) or DTX (10 mg/kg/day) were 76% and 85% smaller than the tumors of negative control mice (*p<0.0001). The average weightof mice was 18.1 g and no statistically significant difference was detected among groups during the study. Alopecia was only observed in all DTX-treated mice. The survival rate was 100% for the control and BisBAL NP groups, but one DTX-treated mouse died at the end of the treatment period. The histopathological analysis revealed that exposure to BisBAL NP was cytotoxic for tumor tissue only, without affecting the liver or kidney. Conclusion: BisBAL NP decreased the tumor growing in a mouse melanoma model without secondary effects, constituting an innovative low-cost alternative to treat melanoma.

Original language	English
Pages (from-to)	2548-2557
Number of pages	10
Journal	Anti-Cancer Agents in Medicinal Chemistry
Volume	22
Issue number	14
Early online date	15 Feb 2022
DOIs	https://doi.org/10.2174/1871520622666220215124434
Publication status	Published - 2022

Bibliographical note

Funding Information:
This research study has been supported by CONACyT, grant A1-S-20148.

Funding Information:
The authors want to thank CONACyT for the grant A1-S-20148; an approved project by the Sectorial Fund for Education Research. The authors thank Ricardo Gaxiola-Centeno from CINVESTAV-Mexico for mice maintenance, and Horacio Alejandro Ovalle-Estrada from the University of Monterrey (UDEM) for technical support.

Publisher Copyright:
© 2022 Bentham Science Publishers.

Access to Document

10.2174/1871520622666220215124434

Cite this

García-Cuellar, C. M., Cabral-Romero, C., Hernández-Delgadillo, R., Solis-Soto, J. M., Meester, I., Sánchez-Pérez, Y., Nakagoshi-Cepeda, S. E., Pineda-Aguilar, N., Sánchez-Nájera, R. I., Nakagoshi-Cepeda, M. A. A., & Chellam, S. (2022). Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model. Anti-Cancer Agents in Medicinal Chemistry, 22(14), 2548-2557. https://doi.org/10.2174/1871520622666220215124434

@article{e0fefbeb654f414099deac1b94749f3f,

title = "Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model",

abstract = "Aim: The objective of this study was to analyze the antitumor effect of BisBAL NP in a mouse melanoma model. Materials and Methods: The antitumor activity of BisBAL NP on murine B16-F10 melanoma cells was determined both in vitro (PrestoBlue cell viability assay and Live/Dead fluorescence) and in vivo, in a mouse model, with the following 15-day treatments: BisBAL NP, negative control (PBS), and cell-death control (docetaxel; DTX). Mouse survival and weight, as well as the tumor volume, were recorded daily during the in vivo study. Results: BisBAL NP were homogeneous in size (mean diameter, 14.7 nm) and bismuth content. In vitro, 0.1 mg/mL BisBAL NP inhibited B16-F10 cell growth stronger (88%) than 0.1 mg/mL DTX (82%) (*p<0.0001). In vivo, tumors in mice treated with BisBAL NP (50 mg/kg/day) or DTX (10 mg/kg/day) were 76% and 85% smaller than the tumors of negative control mice (*p<0.0001). The average weightof mice was 18.1 g and no statistically significant difference was detected among groups during the study. Alopecia was only observed in all DTX-treated mice. The survival rate was 100% for the control and BisBAL NP groups, but one DTX-treated mouse died at the end of the treatment period. The histopathological analysis revealed that exposure to BisBAL NP was cytotoxic for tumor tissue only, without affecting the liver or kidney. Conclusion: BisBAL NP decreased the tumor growing in a mouse melanoma model without secondary effects, constituting an innovative low-cost alternative to treat melanoma.",

author = "Garc{\'i}a-Cuellar, {Claudia Mar{\'i}a} and Claudio Cabral-Romero and Rene Hern{\'a}ndez-Delgadillo and Solis-Soto, {Juan Manuel} and Irene Meester and Yesennia S{\'a}nchez-P{\'e}rez and Nakagoshi-Cepeda, {Sergio Eduardo} and Nayely Pineda-Aguilar and S{\'a}nchez-N{\'a}jera, {Rosa Isela} and Nakagoshi-Cepeda, {Mar{\'i}a Argelia Akemi} and Shankararaman Chellam",

note = "Funding Information: This research study has been supported by CONACyT, grant A1-S-20148. Funding Information: The authors want to thank CONACyT for the grant A1-S-20148; an approved project by the Sectorial Fund for Education Research. The authors thank Ricardo Gaxiola-Centeno from CINVESTAV-Mexico for mice maintenance, and Horacio Alejandro Ovalle-Estrada from the University of Monterrey (UDEM) for technical support. Publisher Copyright: {\textcopyright} 2022 Bentham Science Publishers.",

year = "2022",

doi = "10.2174/1871520622666220215124434",

language = "English",

volume = "22",

pages = "2548--2557",

journal = "Anti-Cancer Agents in Medicinal Chemistry",

issn = "1871-5206",

publisher = "Bentham Science Publishers",

number = "14",

}

García-Cuellar, CM, Cabral-Romero, C, Hernández-Delgadillo, R, Solis-Soto, JM, Meester, I, Sánchez-Pérez, Y, Nakagoshi-Cepeda, SE, Pineda-Aguilar, N, Sánchez-Nájera, RI, Nakagoshi-Cepeda, MAA & Chellam, S 2022, 'Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model', Anti-Cancer Agents in Medicinal Chemistry, vol. 22, no. 14, pp. 2548-2557. https://doi.org/10.2174/1871520622666220215124434

TY - JOUR

T1 - Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model

AU - García-Cuellar, Claudia María

AU - Cabral-Romero, Claudio

AU - Hernández-Delgadillo, Rene

AU - Solis-Soto, Juan Manuel

AU - Meester, Irene

AU - Sánchez-Pérez, Yesennia

AU - Nakagoshi-Cepeda, Sergio Eduardo

AU - Pineda-Aguilar, Nayely

AU - Sánchez-Nájera, Rosa Isela

AU - Nakagoshi-Cepeda, María Argelia Akemi

AU - Chellam, Shankararaman

N1 - Funding Information: This research study has been supported by CONACyT, grant A1-S-20148. Funding Information: The authors want to thank CONACyT for the grant A1-S-20148; an approved project by the Sectorial Fund for Education Research. The authors thank Ricardo Gaxiola-Centeno from CINVESTAV-Mexico for mice maintenance, and Horacio Alejandro Ovalle-Estrada from the University of Monterrey (UDEM) for technical support. Publisher Copyright: © 2022 Bentham Science Publishers.

PY - 2022

Y1 - 2022

N2 - Aim: The objective of this study was to analyze the antitumor effect of BisBAL NP in a mouse melanoma model. Materials and Methods: The antitumor activity of BisBAL NP on murine B16-F10 melanoma cells was determined both in vitro (PrestoBlue cell viability assay and Live/Dead fluorescence) and in vivo, in a mouse model, with the following 15-day treatments: BisBAL NP, negative control (PBS), and cell-death control (docetaxel; DTX). Mouse survival and weight, as well as the tumor volume, were recorded daily during the in vivo study. Results: BisBAL NP were homogeneous in size (mean diameter, 14.7 nm) and bismuth content. In vitro, 0.1 mg/mL BisBAL NP inhibited B16-F10 cell growth stronger (88%) than 0.1 mg/mL DTX (82%) (*p<0.0001). In vivo, tumors in mice treated with BisBAL NP (50 mg/kg/day) or DTX (10 mg/kg/day) were 76% and 85% smaller than the tumors of negative control mice (*p<0.0001). The average weightof mice was 18.1 g and no statistically significant difference was detected among groups during the study. Alopecia was only observed in all DTX-treated mice. The survival rate was 100% for the control and BisBAL NP groups, but one DTX-treated mouse died at the end of the treatment period. The histopathological analysis revealed that exposure to BisBAL NP was cytotoxic for tumor tissue only, without affecting the liver or kidney. Conclusion: BisBAL NP decreased the tumor growing in a mouse melanoma model without secondary effects, constituting an innovative low-cost alternative to treat melanoma.

AB - Aim: The objective of this study was to analyze the antitumor effect of BisBAL NP in a mouse melanoma model. Materials and Methods: The antitumor activity of BisBAL NP on murine B16-F10 melanoma cells was determined both in vitro (PrestoBlue cell viability assay and Live/Dead fluorescence) and in vivo, in a mouse model, with the following 15-day treatments: BisBAL NP, negative control (PBS), and cell-death control (docetaxel; DTX). Mouse survival and weight, as well as the tumor volume, were recorded daily during the in vivo study. Results: BisBAL NP were homogeneous in size (mean diameter, 14.7 nm) and bismuth content. In vitro, 0.1 mg/mL BisBAL NP inhibited B16-F10 cell growth stronger (88%) than 0.1 mg/mL DTX (82%) (*p<0.0001). In vivo, tumors in mice treated with BisBAL NP (50 mg/kg/day) or DTX (10 mg/kg/day) were 76% and 85% smaller than the tumors of negative control mice (*p<0.0001). The average weightof mice was 18.1 g and no statistically significant difference was detected among groups during the study. Alopecia was only observed in all DTX-treated mice. The survival rate was 100% for the control and BisBAL NP groups, but one DTX-treated mouse died at the end of the treatment period. The histopathological analysis revealed that exposure to BisBAL NP was cytotoxic for tumor tissue only, without affecting the liver or kidney. Conclusion: BisBAL NP decreased the tumor growing in a mouse melanoma model without secondary effects, constituting an innovative low-cost alternative to treat melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85132161530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132161530&partnerID=8YFLogxK

U2 - 10.2174/1871520622666220215124434

DO - 10.2174/1871520622666220215124434

M3 - Article

C2 - 35168526

SN - 1871-5206

VL - 22

SP - 2548

EP - 2557

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

IS - 14

ER -

Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this